SynCore Biotechnology Co Ltd Cash Flow-to-Debt Ratio
SynCore Biotechnology Co Ltd cash flow-to-debt ratio. SynCore Biotechnology Co Ltd (4192) has a Cash Flow-to-Debt Ratio of -0.48x as of September 2025, meaning its operating cash flow of NT$-7.18 Million could theoretically repay 0% of its total liabilities (NT$14.88 Million) in one year. Check how high is SynCore Biotechnology Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of SynCore Biotechnology Co Ltd (2015–2024)
Cash flow-to-debt ratio of SynCore Biotechnology Co Ltd from 2015 to 2024. Historical debt coverage capacity for SynCore Biotechnology Co Ltd across 10 annual periods. Also explore 4192 net asset momentum to track the company's year-over-year net asset growth rate.
SynCore Biotechnology Co Ltd Cash Flow-to-Debt Ratio by Year (2015–2024)
SynCore Biotechnology Co Ltd cash flow-to-debt ratio by year from 2015 to 2024. Year-by-year debt coverage analysis for SynCore Biotechnology Co Ltd. For the full cash flow conversion analysis, see SynCore Biotechnology Co Ltd cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.13x | NT$-49.24 Million | NT$23.11 Million | ▲ +45.1% |
| 2023 | -3.88x | NT$-82.37 Million | NT$21.23 Million | ▼ -247.4% |
| 2022 | -1.12x | NT$-209.61 Million | NT$187.64 Million | ▼ -85.4% |
| 2021 | -0.60x | NT$-229.86 Million | NT$381.52 Million | ▲ +32.8% |
| 2020 | -0.90x | NT$-316.63 Million | NT$353.41 Million | ▲ +67.5% |
| 2019 | -2.76x | NT$-418.57 Million | NT$151.84 Million | ▲ +0.7% |
| 2018 | -2.78x | NT$-272.26 Million | NT$98.11 Million | ▼ -72.1% |
| 2017 | -1.61x | NT$-201.96 Million | NT$125.28 Million | ▼ -22.7% |
| 2016 | -1.31x | NT$-195.09 Million | NT$148.46 Million | ▼ -55.4% |
| 2015 | -0.85x | NT$-156.03 Million | NT$184.46 Million | — |